Comparing Lucira Health (NASDAQ:LHDXQ) and Myriad Genetics (NASDAQ:MYGN)
Comparing Lucira Health (NASDAQ:LHDXQ) and Myriad Genetics (NASDAQ:MYGN)
Myriad Genetics (NASDAQ:MYGN – Get Rating) and Lucira Health (NASDAQ:LHDXQ – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Myriad Genetics（纳斯达克股票代码：MYGN — 获取评级）和 Lucira Health（纳斯达克股票代码：LHDXQ — 获取评级）都是小型医疗公司，但哪家更胜一筹？我们将根据两家公司的风险实力、估值、收益、股息、机构所有权、盈利能力和分析师建议进行比较。
Valuation & Earnings
估值与收益
This table compares Myriad Genetics and Lucira Health's gross revenue, earnings per share (EPS) and valuation.
该表比较了Myriad Genetics和Lucira Health的总收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Myriad Genetics | $678.40 million | 2.63 | -$112.00 million | ($1.39) | -15.75 |
| Lucira Health | $93.06 million | 0.02 | -$64.83 million | ($3.58) | -0.01 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 无数的遗传学 | 6.7840 亿美元 | 2.63 | -1.120 亿美元 | (1.39 美元) | -15.75 |
| 露西拉健康 | 9306 万美元 | 0.02 | -6,483 万美元 | (3.58 美元) | -0.01 |
Lucira Health has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.
Lucira Health的收入较低，但收益高于Myriad Genetics。Myriad Genetics的交易市盈率低于Lucira Health，这表明它目前是这两只股票中更实惠的一只。
Analyst Ratings
分析师评级
This is a summary of current ratings and price targets for Myriad Genetics and Lucira Health, as provided by MarketBeat.
这是MarketBeat提供的Myriad Genetics和Lucira Health当前评级和目标价格的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Myriad Genetics | 0 | 2 | 1 | 0 | 2.33 |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 无数的遗传学 | 0 | 2 | 1 | 0 | 2.33 |
| 露西拉健康 | 0 | 0 | 0 | 0 | 不适用 |
Myriad Genetics currently has a consensus target price of $27.00, suggesting a potential upside of 23.34%. Given Myriad Genetics' higher possible upside, research analysts clearly believe Myriad Genetics is more favorable than Lucira Health.
Myriad Genetics目前的共识目标价格为27.00美元，表明潜在的上涨空间为23.34％。鉴于Myriad Genetics可能有更高的上行空间，研究分析师显然认为Myriad Genetics比Lucira Health更有利。
Insider & Institutional Ownership
内部所有权和机构所有权
99.1% of Myriad Genetics shares are held by institutional investors. Comparatively, 57.0% of Lucira Health shares are held by institutional investors. 1.8% of Myriad Genetics shares are held by insiders. Comparatively, 30.4% of Lucira Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Myriad Genetics的99.1％股票由机构投资者持有。相比之下，Lucira Health的股票中有57.0％由机构投资者持有。Myriad Genetics的1.8％的股票由内部人士持有。相比之下，Lucira Health的股票中有30.4％由内部人士持有。强大的机构所有权表明，捐赠基金、对冲基金和大型基金经理认为，从长远来看，股票的表现将优于市场。
Profitability
盈利能力
This table compares Myriad Genetics and Lucira Health's net margins, return on equity and return on assets.
该表比较了Myriad Genetics和Lucira Health的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Myriad Genetics | -16.51% | -5.83% | -4.42% |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 无数的遗传学 | -16.51% | -5.83% | -4.42% |
| 露西拉健康 | -67.54% | -13.55% | -8.47% |
Volatility and Risk
波动性和风险
Myriad Genetics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Lucira Health has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500.
Myriad Genetics的beta值为1.84，这表明其股价的波动性比标准普尔500指数高84％。相比之下，Lucira Health的beta值为3.36，这表明其股价的波动性比标准普尔500指数高236％。
Summary
摘要
Myriad Genetics beats Lucira Health on 9 of the 13 factors compared between the two stocks.
在两只股票比较的13个因素中，Myriad Genetics在9个因素上击败了Lucira Health。
About Myriad Genetics
关于《万里德遗传学》
(Get Rating)
（获取评分）
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Myriad Genetics, Inc. 从事变革性分子诊断测试的发现、开发和营销。它通过诊断和其他部门运营。诊断部门提供测试和合作开发测试服务，旨在评估个人在以后的生活中患上疾病的风险。其他部门为制药、生物技术和医学研究行业、研发和患者临床服务提供测试产品和服务，还包括企业服务。该公司由 Walter A. Gilbert、Mark H. Skolnick 和 Peter D. Meldrum 于 1991 年 5 月创立，总部位于犹他州盐湖城。
About Lucira Health
关于 Lucira Health
(Get Rating)
（获取评分）
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Lucira Health Inc. 是一家医疗技术公司。它专注于变革性和传染病检测试剂盒的开发和商业化。Lucira Health Inc. 总部位于加利福尼亚州的埃默里维尔。
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
接收《Myriad Genetics Daily》的 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Myriad Genetics及相关公司的最新新闻和分析师评级的简明每日摘要。